Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRX246 in Intermittent Explosive Disorder
NCT02055638Phase 2Completed
- Sponsor
- Azevan Pharmaceuticals
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intermittent explosive disorder (IED) comparing SRX246 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at 8 weeks. Started May 2014; status: completed.
02
Drugs
SRX246
03
Conditions
intermittent explosive disorder (IED)
Beyond the preview
Go deeper on NCT02055638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055638.